Humacyte is engaged in the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues. Co. is utilizing its technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The HUMA stock yearly return is shown above.
The yearly return on the HUMA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HUMA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|